Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurren...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
RenJi Hospital
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT07310420 · Advanced Breast Cancer
NCT06595563 · HER2-positive Metastatic Breast Cancer, HER2-positive Advanced Breast Cancer
NCT06997029 · Advanced Solid Tumor, Advanced Breast Cancer, and more
NCT07347600 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions